Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Ancilia Biosciences Announces Closing of $4.2 Million Financing led by Safar Partners

Jul 17, 2024•almost 2 years ago

Contract Type

partnership

New YorkBiotechnology

Description

Ancilia Biosciences, Inc. announced the closing of a $4.2 million financing led by Safar Partners, with participation from other institutional and private investors. The funding will allow the company to further build out and scale their platforms and position them for a subsequent financing round later this year.

Company Information

Company

Ancilia Biosciences

Location

3960 BROADWAY, 6TH FLOOR

New York, New York, United States

About

Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Ancilia Biosciences's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months